BMO’s Evan Seigerman: More clarity out of the FDA could drive smaller biotech names in 2026
BMO’s Evan Seigerman joins ‘Closing Bell’ to talk biopharma stocks heading into the new year.
BMO’s Evan Seigerman joins ‘Closing Bell’ to talk biopharma stocks heading into the new year.
